Concepts (80)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| Arthritis, Infectious | 1 | 2017 | 111 | 0.60 | Why? |
| Antibodies, Antinuclear | 1 | 2017 | 234 | 0.58 | Why? |
| Autoantibodies | 2 | 2019 | 2094 | 0.39 | Why? |
| Hepatitis C, Chronic | 1 | 2017 | 973 | 0.34 | Why? |
| Hepacivirus | 1 | 2017 | 1509 | 0.34 | Why? |
| Post-Exposure Prophylaxis | 2 | 2020 | 472 | 0.30 | Why? |
| Alaska | 1 | 2017 | 100 | 0.17 | Why? |
| Blood Specimen Collection | 1 | 2021 | 387 | 0.17 | Why? |
| Proof of Concept Study | 1 | 2019 | 696 | 0.17 | Why? |
| Immunoglobulin G | 4 | 2021 | 21571 | 0.16 | Why? |
| Adaptor Proteins, Signal Transducing | 1 | 2019 | 502 | 0.15 | Why? |
| Radiology Department, Hospital | 2 | 2020 | 805 | 0.14 | Why? |
| Cholesterol, HDL | 1 | 2017 | 439 | 0.13 | Why? |
| Mass Spectrometry | 1 | 2019 | 1165 | 0.13 | Why? |
| Analysis of Variance | 1 | 2017 | 950 | 0.13 | Why? |
| Lipids | 1 | 2017 | 1079 | 0.10 | Why? |
| Antibodies, Viral | 5 | 2021 | 51949 | 0.09 | Why? |
| Age Distribution | 1 | 2017 | 3567 | 0.08 | Why? |
| Blood Donors | 1 | 2021 | 2956 | 0.08 | Why? |
| Hydroxychloroquine | 2 | 2020 | 12447 | 0.08 | Why? |
| Self Report | 1 | 2017 | 3802 | 0.07 | Why? |
| Clinical Laboratory Techniques | 3 | 2020 | 23402 | 0.07 | Why? |
| Washington | 2 | 2020 | 1722 | 0.07 | Why? |
| Health Policy | 2 | 2020 | 6242 | 0.06 | Why? |
| Diagnosis, Differential | 1 | 2017 | 7220 | 0.06 | Why? |
| Occupational Exposure | 1 | 2020 | 4742 | 0.06 | Why? |
| Longitudinal Studies | 1 | 2017 | 9893 | 0.06 | Why? |
| Idaho | 1 | 2020 | 59 | 0.05 | Why? |
| Air Pollutants, Occupational | 1 | 2020 | 108 | 0.05 | Why? |
| Antiviral Agents | 2 | 2020 | 41703 | 0.04 | Why? |
| Betacoronavirus | 4 | 2020 | 204454 | 0.04 | Why? |
| Sensitivity and Specificity | 3 | 2021 | 22971 | 0.04 | Why? |
| Adult | 7 | 2021 | 244371 | 0.03 | Why? |
| Kenya | 1 | 2017 | 887 | 0.03 | Why? |
| Reproducibility of Results | 2 | 2021 | 11304 | 0.03 | Why? |
| Ascorbic Acid | 1 | 2020 | 676 | 0.03 | Why? |
| Antibodies, Neutralizing | 1 | 2021 | 25288 | 0.03 | Why? |
| Rituximab | 1 | 2021 | 1096 | 0.03 | Why? |
| Drug Administration Schedule | 1 | 2020 | 2324 | 0.03 | Why? |
| Multicenter Studies as Topic | 1 | 2020 | 2437 | 0.03 | Why? |
| Male | 8 | 2021 | 367725 | 0.03 | Why? |
| Female | 8 | 2021 | 380317 | 0.03 | Why? |
| Middle Aged | 6 | 2021 | 270681 | 0.03 | Why? |
| Antiretroviral Therapy, Highly Active | 1 | 2017 | 952 | 0.03 | Why? |
| HIV Infections | 1 | 2017 | 11620 | 0.03 | Why? |
| Infection Control | 1 | 2020 | 23131 | 0.03 | Why? |
| Humans | 13 | 2021 | 930598 | 0.03 | Why? |
| Mass Screening | 2 | 2020 | 8005 | 0.03 | Why? |
| Aged, 80 and over | 4 | 2021 | 88759 | 0.03 | Why? |
| Young Adult | 4 | 2021 | 93724 | 0.02 | Why? |
| Cross-Sectional Studies | 1 | 2017 | 53120 | 0.02 | Why? |
| Double-Blind Method | 1 | 2020 | 5988 | 0.02 | Why? |
| Pneumonia, Viral | 4 | 2020 | 243684 | 0.02 | Why? |
| Coronavirus Infections | 4 | 2020 | 253789 | 0.02 | Why? |
| Immunity, Cellular | 1 | 2021 | 3614 | 0.02 | Why? |
| Hospitals, University | 1 | 2020 | 4173 | 0.02 | Why? |
| Disaster Planning | 1 | 2020 | 1680 | 0.02 | Why? |
| Aged | 5 | 2021 | 215776 | 0.02 | Why? |
| Time Factors | 2 | 2020 | 31397 | 0.02 | Why? |
| Serologic Tests | 1 | 2020 | 4359 | 0.02 | Why? |
| Practice Guidelines as Topic | 2 | 2020 | 15421 | 0.02 | Why? |
| Immunization, Passive | 1 | 2021 | 10067 | 0.02 | Why? |
| Seroepidemiologic Studies | 1 | 2020 | 10017 | 0.02 | Why? |
| Occupational Health | 1 | 2020 | 3965 | 0.02 | Why? |
| Treatment Outcome | 2 | 2020 | 51732 | 0.02 | Why? |
| Virus Shedding | 1 | 2020 | 5834 | 0.02 | Why? |
| United States | 2 | 2020 | 46150 | 0.02 | Why? |
| HIV-1 | 1 | 2017 | 3365 | 0.01 | Why? |
| Randomized Controlled Trials as Topic | 1 | 2020 | 10649 | 0.01 | Why? |
| Contact Tracing | 1 | 2020 | 8448 | 0.01 | Why? |
| Adolescent | 2 | 2020 | 86841 | 0.01 | Why? |
| Risk Factors | 2 | 2020 | 71621 | 0.01 | Why? |
| Pandemics | 6 | 2021 | 389249 | 0.01 | Why? |
| Incidence | 1 | 2020 | 25622 | 0.01 | Why? |
| Infectious Disease Transmission, Patient-to-Professional | 1 | 2020 | 9706 | 0.01 | Why? |
| Viral Load | 1 | 2017 | 15850 | 0.01 | Why? |
| Risk Assessment | 1 | 2020 | 25439 | 0.01 | Why? |
| Vaccination | 1 | 2021 | 19050 | 0.01 | Why? |
| Personal Protective Equipment | 1 | 2020 | 15978 | 0.01 | Why? |
| Hospitalization | 1 | 2020 | 54280 | 0.01 | Why? |
Wener's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts
(80)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(104)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_